

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPICI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

organizations  
 NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist  
 Assistant and BLAST plug-in  
 NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL  
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:59:53 ON 14 JUL 2008

=> file registry  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 0.63 0.63

FILE 'REGISTRY' ENTERED AT 13:01:27 ON 14 JUL 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1  
 DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnc/properties.html>

=>  
 Uploading C:\Program Files\Stnexp\Queries\10686809\_NEW\_20080714.str



```

chain nodes :
10 11 12 13 14 15 16 19
ring nodes :
1 2 3 4 5 6 7 8 9 20 21 22 23 24 25 27 28 29 30 31 32
chain bonds :
7-12 8-11 9-10 10-27 12-13 12-15 13-14 13-16 14-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 20-21 20-25 21-22 22-23 23-24
24-25 27-28 27-32 28-29 29-30 30-31 31-32
exact/norm bonds :
5-7 6-9 7-8 8-9 9-10 10-27 12-15 13-14 13-16
exact bonds :
7-12 8-11 12-13 14-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 27-28
27-32 28-29 29-30 30-31 31-32

```

G1:O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 19:CLASS 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:Atom 31:Atom 32:Atom

```

L1           STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 13:01:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -       796 TO ITERATE

100.0% PROCESSED       796 ITERATIONS

138 ANSWERS

SEARCH TIME: 00.00.01


L2           138 SEA SSS FUL L1

=> d scan

L2   138 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN

IN   1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-5-hydroxy-1-  
[(4-hydroxyphenyl)methyl]- $\alpha$ -oxo-

MF   C22 H15 Cl2 N3 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2   138 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN

IN   1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-  
chlorophenyl)methyl]- $\alpha$ -oxo-

MF   C23 H17 Cl N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
178.82	179.45

FILE 'CAPLUS' ENTERED AT 13:02:30 ON 14 JUL 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3  
 FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

L3 112 L2

=> s 13 not py>2003  
 5975564 PY>2003

L4 16 L3 NOT PY>2003

=> s l4 and (cancer? or ?tumor?)  
384094 CANCER?  
666007 ?TUMOR?

L5 4 L4 AND (CANCER? OR ?TUMOR?)

=> d l5 1-4 ibib, abs, hitstr

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2001:915607 CAPLUS

DOCUMENT NUMBER: 136:193482

TITLE: New small-molecule tubulin inhibitors

AUTHOR(S): Bacher, G.; Beckers, T.; Emig, P.; Klenner, T.;  
Kutschert, B.; Nickel, B.

CORPORATE SOURCE: IUPAC Commission, Research & Development Oncology,  
ASTA Medica AG, Frankfurt, 60314, Germany

SOURCE: Pure and Applied Chemistry (2001), 73(9), 1459-1464  
CODEN: PACHAS; ISSN: 0033-4545

PUBLISHER: International Union of Pure and Applied Chemistry

DOCUMENT TYPE: Journal; General Review


LANGUAGE: English

AB A review. The variety of biol. agents directed toward the tubulin system exceeds those acting on DNA, making it an important target for cancer chemotherapy. However, the complicated chemical structures and restricted access to the natural resources, in combination with the development of drug resistance, limit the first generation of natural products. Considerable efforts in the search and synthesis of new synthetic compds., such as small mol. tubulin inhibitors, gave access to novel potential/promising drugs. Among these substances, two series of novel, easily accessible indole classes were identified as tubulin-stabilizing agents. Owing to the synthetic nature, potent in vitro and in vivo antitumoral activity, and efficacy against multidrug-resistant (MDR) tumors, D-24851 and D-64131 have significant potential in cancer treatment.

IT 204205-90-3, D-24851  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (small-mol. tubulin inhibitors)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:783704 CAPLUS

DOCUMENT NUMBER: 136:112307

TITLE: Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and their possible application in drug discovery studies

AUTHOR(S): Schmidt, Mathias; Lu, Yang; Parant, John M.; Lozano, Guillermina; Bacher, Gerald; Beckers, Thomas; Fan, Zhen

CORPORATE SOURCE: Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

SOURCE: Molecular Pharmacology (2001), 60(5), 900-906

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, the differential role of the cyclin-dependent kinase (CDK) inhibitors p21Waf1 and p27Kip1 in cell cycle regulation was proposed for use in screening natural or synthetic compds. for cell cycle-dependent (particularly M phase-dependent) antineoplastic activity. P21Waf1 or p27Kip1 was ectopically expressed with an ecdysone-inducible mammalian expression system in a human colon adenocarcinoma cell line. Induction of p21Waf1 or p27Kip1 expression inhibited the activities of CDK2 and completely arrested cells at G1 phase of the cell cycle by p27Kip1 and at G1 and G2 phases by p21Waf1. We examined the sensitivity of these cells to several antineoplastic agents known to be cell cycle-dependent or -independent. Substantially increased resistance to cell cycle-dependent antineoplastic agents was found in the cells when the expression of p21Waf1 or p27Kip1 was induced. In contrast, only a desensitization to cell cycle-independent antineoplastic agents was found in the cells arrested by p21Waf1 or p27Kip1. Because p21Waf1 induces an addnl. block at G2 phase that inhibits cell entry into M phase, we further examined the difference between p21Waf1- and p27Kip1-induced cells in their sensitivity to D-24851, a novel M phase-dependent compound. We found that induction of p21Waf1 after exposure of the cells to D-24851 conferred stronger resistance than did induction of p27Kip1. Taken together, our results suggest that the differential effect of p21Waf1 and p27Kip1 on cell cycle regulation may be advantageous for screening chemical libraries for novel antineoplastic candidates that are cell cycle-dependent, and M phase-dependent in particular.


IT 204205-90-3, D 24851

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and possible application in drug discovery studies)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS ON SIN

ACCESSION NUMBER: 2001:58000 CAPLUS

DOCUMENT NUMBER: 134:290069

TITLE: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

AUTHOR(S): Bacher, Gerald; Nickel, Bernd; Emig, Peter; Vanhoefer, Udo; Seeber, Siegfried; Shandra, Alexei; Klenner, Thomas; Beckers, Thomas

CORPORATE SOURCE: Department of Cancer Research, ASTA Medica AG, Frankfurt am Main, 60314, Germany

SOURCE: Cancer Research (2001), 61(1), 392-399

CODEN: CNREAS; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N-(pyridin-4-yl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide (D-24851) is a novel synthetic compound that was identified in a cell-based screening assay to discover cytotoxic drugs. D-24851 destabilizes microtubules and blocks cell cycle transition specifically at G2-M phase. The binding site of D-24851 does not overlap with the tubulin binding sites of known microtubule-destabilizing agents like vincristine or colchicine. In vitro, D-24851 has potent cytotoxic activity toward a panel of established human tumor cell lines including SKOV3 ovarian cancer, U87 glioblastoma, and ASPC-1 pancreatic cancer cells. In vivo, oral D-24851 treatment induced complete tumor regressions (cures) in rats bearing Yoshida AH13 sarcomas. Of importance is that the administration of curative doses of D-24851 to the animals revealed no systemic toxicity in terms of body weight loss and neurotoxicity in contrast to the administration of paclitaxel or vincristine. Interestingly, multidrug-resistant cell lines generated by vincristine-driven selection or transfection with the Mr 170,000 P-glycoprotein encoding cDNA were rendered resistant toward paclitaxel, vincristine, or doxorubicin but not towards D-24851 when compared with the parental cells. Because of its synthetic nature, its oral applicability, its potent in vitro and in vivo antitumoral activity, its efficacy against multidrug-resistant tumors, and the lack of neurotoxicity, D-24851 may have significant potential for the treatment of various malignancies.

IT 204205-90-3, D 24851


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2000:814353 CAPLUS

DOCUMENT NUMBER: 133:359224

TITLE: Fatty acid-N-substituted indol-3-glyoxylamide compositions as antitumor agents

INVENTOR(S): Bradley, Matthews O.; Swindell, Charles S.; Anthony, Forrest; Webb, Nigel L.; Fisher, Mark

PATENT ASSIGNEE(S): Protarga, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067802	A1	20001116	WO 2000-US12752	20000510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000048342	A	20001121	AU 2000-48342	20000510
PRIORITY APPLN. INFO.:			US 1999-133292P	P 19990510
			WO 2000-US12752	W 20000510
OTHER SOURCE(S):		MARPAT 133:359224		
GI				




I

AB The present invention pertains to N-substituted indol-3-glyoxyamides that are conjugates of fatty acids and conjugates of I. The conjugates are useful in treating cancer. In an example taxoprexin completely eliminated all measureable tumors in 7 out of 8 mice at 120 mg/kg/day for 5 days while paclitaxel retarded tumor growth for about 4 days.

IT 204205-90-3D, conjugates, with antitumor agents  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty acid-N-substituted indol-3-glyoxyamide compns. as antitumor agents)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:59:53 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 13:01:27 ON 14 JUL 2008

L1 STRUCTURE UPLOADED

L2 138 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:02:30 ON 14 JUL 2008

L3 112 S L2  
 L4 16 S L3 NOT PY>2003  
 L5 4 S L4 AND (CANCER? OR ?TUMOR?)

=> s l3 and (cancer? or ?tumor?)  
 384094 CANCER?  
 666007 ?TUMOR?

L6 45 L3 AND (CANCER? OR ?TUMOR?)

=> s l6 not py>2004  
 4877099 PY>2004

L7 7 L6 NOT PY>2004

=> d l17 1-7 ibib, abs, hitstr  
 L17 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l17 1-7 ibib, abs, hitstr


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:996001 CAPLUS  
 DOCUMENT NUMBER: 141:406065  
 TITLE: Composition comprising a PDE-4 inhibitor and a TNF-alpha antagonist  
 INVENTOR(S): Barsig, Johannes; Weimar, Christian  
 PATENT ASSIGNEE(S): Altana Pharma AG, Germany  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098633	A1	20041118	WO 2004-EP50748	20040510
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: EP 2003-10581 A 20030512  
 AB The invention relates to the combined administration of a PDE4 inhibitor and a TNF $\alpha$  antagonist selected from the group consisting of etanercept, onercept and pegsunercept for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or tumor necrosis factor alpha (TNF $\alpha$ ) activity is detrimental.  
 IT 257892-33-4, AWD 12-281  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (therapeutic activity of phosphodiesterase 4 inhibitors and TNF $\alpha$  antagonists)  
 RN 257892-33-4 CAPLUS  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[4-

fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2004:565834 CAPLUS

DOCUMENT NUMBER: 141:98938

TITLE: Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry  
AUTHOR(S): Stokvis, Ellen; Nan-Offeringa, Lianda G. A. H.; Ouwehand, Mariet; Tibben, Matthijs M.; Rosing, Hilde; Schnaars, Yvonne; Grigat, Martina; Romeis, Peter; Schellens, Jan H. M.; Beijnen, Jos H.

CORPORATE SOURCE: Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, 1066 EC, Neth.

SOURCE: Rapid Communications in Mass Spectrometry (2004), 18(13), 1465-1471

CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The development of a liquid chromatog./tandem mass spectrometric assay for the quant. anal. of the novel tubulin inhibitor D-24851 in human plasma and urine is described. D-24851 and the deuterated internal standard were extracted from 250  $\mu$ L of plasma or urine using hexane/ether (1:1, volume/volume). Subsequently, 10- $\mu$ L aliquots of reconstituted exts. were injected onto an Inertsil ODS anal. column (50 + 2.0 mm internal diameter, 5  $\mu$ m particle size). An eluent consisting of MeOH/5 mM ammonium acetate, 0.004% formic acid in H<sub>2</sub>O (80:20, volume/volume) was pumped at a flow rate of 0.2 mL/min. An API 365 triple quadrupole mass spectrometer was used in the multiple reaction monitoring mode for sensitive detection. For human plasma a dynamic range of 1-1000 ng/mL was validated, and for human urine a range of 0.25-50 ng/mL. Validation was performed according to the most recent FDA guidelines and all results were within requirements. The assay was successfully applied to support a phase I clin. trial with orally administered D-24851.

IT 204205-90-3, D-24851

RL: ANT (Analyte); ANST (Analytical study)  
(quant. anal. of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatog. coupled with tandem mass spectrometry)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:130977 CAPLUS

DOCUMENT NUMBER: 140:281023

TITLE: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations

AUTHOR(S): Draheim, Regina; Egerland, Ute; Rundfeldt, Chris  
CORPORATE SOURCE: Departments of Pharmacology and Molecular Biology, Elbion AG, Radebeul, Germany

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2004), 308(2), 555-563  
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB AWD 12-281 is a potent (IC<sub>50</sub> = 9.7 nM) and highly selective inhibitor of the phosphodiesterase 4 (PDE4) isoenzyme with low affinity to the high-affinity rolipram-binding site. The compound was optimized for topical treatment of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The aim of the present study was to assess the effect of AWD 12-281 in human inflammatory cells. Peripheral blood mononuclear cells (PBMCs), diluted whole blood, and human nasal polyp cells derived from surgically resected nasal polyps from patients with polyposis comprise sources of target tissue cells that can be used to predict anti-inflammatory effects in patients. AWD 12-281 was capable of suppressing the production of cytokines in stimulated PBMCs: interleukin-2 (IL-2, phytohemagglutinin stimulation), IL-5 (Con A stimulation), IL-5 and IL-4 (anti-CD3/anti-CD28 co-stimulation), and lipopolysaccharide-stimulated release of tumor necrosis factor  $\alpha$  (TNF $\alpha$ ). The corresponding values for half-maximum inhibition, EC<sub>50</sub>, for AWD 12-281 were within a narrow range (46-121 nM). Comparing the effect of AWD 12-281 with roflumilast, cilomilast (SB 207499), rolipram (RPR-73401), and 1-(3-nitrophenyl)-3-(4-pyridylmethyl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (RS-25344-000), it could be shown that the PDE4 inhibitory activity was closely correlated with inhibitory potential as measured by the above-described assays. AWD 12-281 was also shown to suppress TNF $\alpha$  release in dispersed nasal polyps (EC<sub>50</sub> = 111 nM) and

in diluted whole blood (EC50 = 934 nM). The reduced activity in human blood may be related to high plasma protein binding. Currently, phase II clin. studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis.


IT 257892-33-4, AWD 12-281

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiinflammatory potential of PDE4 inhibitor AWD 12-281 in human cell preps.)

RN 257892-33-4 CAPLUS

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:915607 CAPLUS

DOCUMENT NUMBER: 136:193482

TITLE: New small-molecule tubulin inhibitors

AUTHOR(S): Bacher, G.; Beckers, T.; Emig, F.; Klenner, T.; Kutschert, B.; Nickel, B.

CORPORATE SOURCE: IUPAC Commission, Research & Development Oncology, ASTA Medica AG, Frankfurt, 60314, Germany

SOURCE: Pure and Applied Chemistry (2001), 73(9), 1459-1464 CODEN: PACHAS; ISSN: 0033-4545

PUBLISHER: International Union of Pure and Applied Chemistry

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. The variety of biol. agents directed toward the tubulin system exceeds those acting on DNA, making it an important target for cancer chemotherapy. However, the complicated chemical structures and restricted access to the natural resources, in combination with the development of drug resistance, limit the first generation of natural products. Considerable efforts in the search and synthesis of new synthetic compds., such as small mol. tubulin inhibitors, gave access to novel potential/promising drugs. Among these substances, two series of novel, easily accessible indole classes were identified as tubulin-destabilizing agents. Owing to the synthetic nature, potent in vitro and in vivo antitumoral activity, and efficacy against multidrug-resistant (MDR) tumors, D-24851 and D-64131 have significant potential in cancer treatment.


IT 204205-90-3, D-24851

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(small-mol. tubulin inhibitors)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2001:783704 CAPLUS

DOCUMENT NUMBER: 136:112307

TITLE: Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and their possible application in drug discovery studies

AUTHOR(S): Schmidt, Mathias; Lu, Yang; Parant, John M.; Lozano, Guillermina; Bacher, Gerald; Beckers, Thomas; Fan, Zhen

CORPORATE SOURCE: Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

SOURCE: Molecular Pharmacology (2001), 60(5), 900-906  
CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, the differential role of the cyclin-dependent kinase (CDK) inhibitors p21Waf1 and p27Kip1 in cell cycle regulation was proposed for use in screening natural or synthetic compds. for cell cycle-dependent (particularly M phase-dependent) antineoplastic activity. P21Waf1 or p27Kip1 was ectopically expressed with an ecdysone-inducible mammalian expression system in a human colon adenocarcinoma cell line. Induction of p21Waf1 or p27Kip1 expression inhibited the activities of CDK2 and completely arrested cells at G1 phase of the cell cycle by p27Kip1 and at G1 and G2 phases by p21Waf1. We examined the sensitivity of these cells to several antineoplastic agents known to be cell cycle-dependent or -independent. Substantially increased resistance to cell cycle-dependent antineoplastic agents was found in the cells when the expression of p21Waf1 or p27Kip1 was induced. In contrast, only a desensitization to cell cycle-independent antineoplastic agents was found in the cells arrested by p21Waf1 or p27Kip1. Because p21Waf1 induces an addnl. block at G2 phase that inhibits cell entry into M phase, we further examined the difference between p21Waf1- and p27Kip1-induced cells in their sensitivity to D-24851, a novel M phase-dependent compound. We found that induction of p21Waf1 after exposure of the cells to D-24851 conferred stronger


resistance than did induction of p27Kipl. Taken together, our results suggest that the differential effect of p21Waf1 and p27Kipl on cell cycle regulation may be advantageous for screening chemical libraries for novel antineoplastic candidates that are cell cycle-dependent, and M phase-dependent in particular.

IT 204205-90-3, D 24851

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(differential roles of p21Waf1 and p27Kipl in modulating chemosensitivity and possible application in drug discovery studies)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:58000 CAPLUS

DOCUMENT NUMBER: 134:290069

TITLE: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

AUTHOR(S): Bacher, Gerald; Nickel, Bernd; Emig, Peter; Vanhoefer, Udo; Seeber, Siegfried; Shandra, Alexei; Klenner, Thomas; Beckers, Thomas

CORPORATE SOURCE: Department of Cancer Research, ASTA Medica AG, Frankfurt am Main, 60314, Germany

SOURCE: Cancer Research (2001), 61(1), 392-399  
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal


LANGUAGE: English

AB N-(pyridin-4-yl)-[1-[(4-chlorobenzyl)indol-3-yl]glyoxy]amide (D-24851) is a novel synthetic compound that was identified in a cell-based screening assay to discover cytotoxic drugs. D-24851 destabilizes microtubules and blocks cell cycle transition specifically at G2-M phase. The binding site of D-24851 does not overlap with the tubulin binding sites of known microtubule-destabilizing agents like vincristine or colchicine. In vitro, D-24851 has potent cytotoxic activity toward a panel of established human tumor cell lines including SKOV3 ovarian cancer, U87 glioblastoma, and ASPC-1 pancreatic cancer cells. In vivo, oral D-24851 treatment induced complete tumor regressions (cures) in rats bearing Yoshida AH13 sarcomas. Of importance is that the administration of curative doses of D-24851 to the animals revealed no



systemic toxicity in terms of body weight loss and neurotoxicity in contrast to the administration of paclitaxel or vincristine. Interestingly, multidrug-resistant cell lines generated by vincristine-driven selection or transfection with the Mr 170,000 P-glycoprotein encoding cDNA were rendered resistant toward paclitaxel, vincristine, or doxorubicin but not towards D-24851 when compared with the parental cells. Because of its synthetic nature, its oral applicability, its potent in vitro and in vivo antitumoral activity, its efficacy against multidrug-resistant tumors, and the lack of neurotoxicity, D-24851 may have significant potential for the treatment of various malignancies.

IT 204205-90-3, D 24851  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity)  
 RN 204205-90-3 CAPLUS  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:814353 CAPLUS  
 DOCUMENT NUMBER: 133:359224  
 TITLE: Fatty acid-N-substituted indol-3-glyoxylamide compositions as antitumor agents  
 INVENTOR(S): Bradley, Matthews O.; Swindell, Charles S.; Anthony, Forrest; Webb, Nigel L.; Fisher, Mark  
 PATENT ASSIGNEE(S): Protarga, Inc., USA  
 SOURCE: PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067802	A1	20001116	WO 2000-US12752	20000510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000048342 A 20001121 AU 2000-48342 20000510  
 PRIORITY APPLN. INFO.: US 1999-133292P P 19990510  
 WO 2000-US12752 W 20000510

OTHER SOURCE(S): MARPAT 133:359224  
 GI




AB The present invention pertains to N-substituted indol-3-glyoxylamides that are conjugates of fatty acids and conjugates of I. The conjugates are useful in treating cancer. In an example taxoprexin completely eliminated all measureable tumors in 7 out of 8 mice at 120 mg/kg/day for 5 days while paclitaxel retarded tumor growth for about 4 days.

IT 204205-90-3D, conjugates, with antitumor agents  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fatty acid-N-substituted indol-3-glyoxylamide compns. as antitumor agents)

RN 204205-90-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:59:53 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 13:01:27 ON 14 JUL 2008

L1 STRUCTURE UPLOADED  
L2 138 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:02:30 ON 14 JUL 2008

L3 112 S L2  
L4 16 S L3 NOT PY>2003  
L5 4 S L4 AND (CANCER? OR ?TUMOR?)  
L6 45 S L3 AND (CANCER? OR ?TUMOR?)  
L7 7 S L6 NOT PY>2004

=> file wpids uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	75.07	254.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.80	-8.80

FILE 'WPIDS' ENTERED AT 13:05:21 ON 14 JUL 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 13:05:21 ON 14 JUL 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2

SAMPLE SEARCH INITIATED 13:05:27 FILE 'WPIDS'  
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 7 ANSWERS  
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 22 TO 238  
PROJECTED ANSWERS: 7 TO 149

L8 83 L2

=> s l8 and (cancer? or ?tumor?)

L9 38 L8 AND (CANCER? OR ?TUMOR?)

=> d l9 1-38 ibib, abs, hitstr

L9 ANSWER 1 OF 38 USPATFULL on SIN

ACCESSION NUMBER: 2008:152208 USPATFULL

TITLE: Combination Of Cb2 Modulators And Pde4 Inhibitors For  
Use In Medicine

INVENTOR(S): Brown, Andrew James, Essex, UNITED KINGDOM  
Connor, Helen Elizabeht, Hertfordshire, UNITED KINGDOM  
Eatherton, Andrew John, Essex, UNITED KINGDOM  
Giblin, Gerard Martin Paul, Essex, UNITED KINGDOM

Green, Richard Howard, Hertfordshire, UNITED KINGDOM  
 Doughty, Jennifer Margaret, Gorham, ME, UNITED STATES  
 legal representative  
 Jandu, Karamjit Singh, Essex, UNITED KINGDOM  
 Knowles, Richard Graham, Hertfordshire, UNITED KINGDOM  
 Mitchell, William Leonard, Essex, UNITED KINGDOM  
 Naylor, Alan, Essex, UNITED KINGDOM  
 O'Shaughnessy, Celestine Theresa, Essex, UNITED KINGDOM  
 Palombi, Giovanni, Milan, ITALY  
 Rawlings, Derek Anthony, Essex, UNITED KINGDOM  
 Slingsby, Brian Peter, Essex, UNITED KINGDOM  
 Tralau-Stewart, Catherine Jane, Hertfordshire, UNITED  
 KINGDOM  
 Whittington, Andrew Richard, Hertfordshire, UNITED  
 KINGDOM  
 Williamson, Richard Alexander, Hertfordshire, UNITED  
 KINGDOM  
 PATENT ASSIGNEE(S): Glaxo Group Limited (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080132505	A1	20080605
APPLICATION INFO.:	US 2005-597527	A1	20050201 (10)
	WO 2005-GB348		20050201
			20061102 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2004-2355	20040203
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	

NUMBER OF CLAIMS: 6  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 8699  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Combination of one or more CB2 modulators and one or more PDE4  
 inhibitors, and method of treating conditions which are mediated by the  
 activity of CB2 receptors or conditions which are mediated by PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 257892-33-4

(PDE4 inhibitor, combination therapy agent; preparation of  
 aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with  
 PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic  
 diseases)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-  
 fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 2 OF 38 USPATFULL on SIN

ACCESSION NUMBER: 2008:98507 USPATFULL

TITLE: Pharmaceutical Composition

INVENTOR(S): Harada, Daisuke, Sunto-gun, JAPAN

Kobayashi, Katsuya, Sunto-gun, JAPAN

Manabe, Haruhiko, Sunto-gun, JAPAN

Ohshima, Etsuo, Nagareyama-shi, JAPAN

PATENT ASSIGNEE(S): KYOWA HAKKO KOGYO CO., LTD., Chiyoda-ku, Tokyo, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080085858	A1	20080410
APPLICATION INFO.:	US 2005-576970	A1	20051013 (11)
	WO 2005-JP18854		20051013
			20070410 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2004-299104	20041013
	JP 2005-113265	20050411
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1390	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention provides a pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases to be administered simultaneously or separately with an interval comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, as active ingredients; and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4

(phosphodiesterase IV inhibitor and immunosuppressant combinations for

treatment of chronic skin diseases)  
 RN 257892-33-4 USPATFULL  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 3 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2008:65210 USPATFULL  
 TITLE: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties  
 INVENTOR(S): Nickel, Bernd, Muhlital, GERMANY, FEDERAL REPUBLIC OF  
 Bacher, Gerald, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
 Klenner, Thomas, Ingelheim, GERMANY, FEDERAL REPUBLIC OF  
 Beckers, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
 Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
 Engel, Jorgen, Alzenau, GERMANY, FEDERAL REPUBLIC OF  
 Bruyneel, Erik, Harelbeke, BELGIUM  
 Kamp, Gunter, Munster, GERMANY, FEDERAL REPUBLIC OF  
 Peters, Kirsten, Munster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080057124	A1	20080306
APPLICATION INFO.:	US 2007-894729	A1	20070820 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-686809, filed on 17 Oct 2003, PENDING Continuation of Ser. No. US 2000-492531, filed on 27 Jan 2000, GRANTED, Pat. No. US 6693119 Continuation-in-part of Ser. No. US 1999-285058, filed on 2 Apr 1999, GRANTED, Pat. No. US 6232327		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
	DE 1999-19946301	19990928
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 537

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of N-substituted indole-3-glyoxylamides of the general ##STR1## and to pharmaceutical compositions having antitumor action.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
204205-82-3P 204205-85-6P 204205-86-7P  
204205-90-3P 204205-91-4P 204205-92-5P  
204205-95-8P 204205-96-9P 204205-97-0P  
204206-01-9P 204206-03-1P 245661-24-9P  
245661-25-0P 245661-26-1P 245661-28-3P  
245661-29-4P 245661-30-7P 245661-31-8P  
245661-38-5P 245661-39-6P 245661-41-0P  
245661-42-1P 245661-43-2P 245661-47-6P  
245661-48-7P 245661-49-8P 245661-50-1P  
245661-51-2P 245661-52-3P 245661-53-4P  
245661-54-5P 245661-55-6P

(preparation of indolyglyoxylamides as antitumor agents)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)



RN 204205-85-6 USPATFULL


CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 204205-86-7 USPATFULL


CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)






RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-  
pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 245661-39-6 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 245661-41-0 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro- $\alpha$ -oxo-N-4-

pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 245661-48-7 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)-α-oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 4 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2008:58534 USPATFULL

TITLE: Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms

INVENTOR(S): Lerner, Adam, Newton, MA, UNITED STATES

Tiwari, Sanjay, Buchholz, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, UNITED STATES, 02215 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080051379	A1	20080228
APPLICATION INFO.:	US 2005-792172	A1	20051201 (11)
	WO 2005-US43613		20051201
			20071106 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-632207P	20041201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	RONALD I. EISENSTEIN, 100 SUMMER STREET, NIXON PEABODY LLP, BOSTON, MA, 02110, US	

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 1456

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors and a glucocorticoid. Preferably, the combination of the PDE4 inhibitor and the glucocorticoid has a synergistic effect on apoptosis such that the level of apoptosis induced is greater than the level that would be expected by simply adding a PDE4 inhibitor to a glucocorticoid.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4, AWD 12-281 257892-33-4D, AWD 12-281, derivs. 444659-44-3, AWD 12-343 444659-44-3D, AWD 12-343, derivs.

(phosphodiesterase 4 inhibitors with glucocorticoids for treatment of peripheral B-cell neoplasms)


RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)




RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)




RN 444659-44-3 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 444659-44-3 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo- (CA INDEX NAME)



L9 ANSWER 5 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2008:30814 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having antitumor action

INVENTOR(S): Nickel, Bernd, Muhltal, GERMANY, FEDERAL REPUBLIC OF  
 Szelenyi, Istvan, Schwaig, GERMANY, FEDERAL REPUBLIC OF  
 Schmidt, Jurgen, Uhdingen Muhhofen, GERMANY, FEDERAL REPUBLIC OF  
 Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
 Reichert, Dietmar, Eschau, GERMANY, FEDERAL REPUBLIC OF  
 Gunther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF  
 Brune, Kay, Marloffstein, GERMANY, FEDERAL REPUBLIC OF  
 Le Baut, Guillaume, Saint Sebastian/Loire, FRANCE  
 PATENT ASSIGNEE(S): Asta Medica Aktiengesellschaft (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080027110	A1	20080131
APPLICATION INFO.:	US 2007-894591	A1	20070820 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-309204, filed on 4 Dec 2002, PENDING Continuation of Ser. No. US 2001-810604,		

filed on 19 Mar 2001, ABANDONED Continuation of Ser.  
No. US 1999-285058, filed on 2 Apr 1999, GRANTED, Pat.  
No. US 6232327


	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1026	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents ##STR1## and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
204205-82-3P 204205-85-6P 204205-86-7P  
204205-90-3P 204205-91-4P 204205-92-5P  
204205-95-8P 204205-96-9P 204205-97-0P  
204206-01-9P 204206-03-1P 245661-24-9P  
245661-25-0P 245661-26-1P 245661-28-3P  
245661-29-4P 245661-30-7P 245661-31-8P  
245661-38-5P 245661-39-6P 245661-41-0P  
245661-42-1P 245661-43-2P 245661-47-6P  
245661-48-7P 245661-49-8P 245661-50-1P  
245661-51-2P 245661-52-3P 245661-53-4P  
245661-54-5P 245661-55-6P  
(preparation of indolylglyoxylamides as antitumor agents)  
RN 204205-78-7 USPATFULL  
CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-  
pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
α-oxo- (CA INDEX NAME)



RN 204205-86-7 USPATFULL


CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA  
INDEX NAME)



RN 204205-90-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-  
pyridinyl- (CA INDEX NAME)






RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy-α-oxo-N-(4-pyridinyl)- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245661-39-6 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 245661-49-8 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-50-1 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 6 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2007:224189 USPATFULL

TITLE: Novel combination of anticholinergics - B2-adrenoceptor

agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Maus, Joachim, Muhlheim, GERMANY, FEDERAL REPUBLIC OF  
Kastrup, Horst, Munster, GERMANY, FEDERAL REPUBLIC OF  
Szelenyi, Istvan, Schwaig, GERMANY, FEDERAL REPUBLIC OF  
Cnota, Peter Jurgen, Bad Homburg, GERMANY, FEDERAL  
REPUBLIC OF  
Bauhofer, Artur, Marburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): MEDA Pharma GmbH & Co. KG, Bad Homburg, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070196285	A1	20070823
APPLICATION INFO.:	US 2006-642967	A1	20061221 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-752058P	20051221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	VENABLE LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1690	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to novel combinations based on anticholinergics,  $\beta$ -sub.2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4, AWD-12-281  
(combination of anticholinergics and  $\beta$ 2-adrenoceptor agonists and antileukotrienes and glucocorticoids for treatment of inflammatory diseases)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 7 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2007:169455 USPATFULL  
TITLE: Combination bacteriolytic therapy for the treatment of tumors  
INVENTOR(S): Dang, Long, Baltimore, MD, UNITED STATES  
Bettegowda, Chetan, Baltimore, MD, UNITED STATES  
Kenzler, Kenneth W., Bel Air, MD, UNITED STATES  
Vogelstein, Bert, Baltimore, MD, UNITED STATES  
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, UNITED STATES, 21218 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070148135	A1	20070628
APPLICATION INFO.:	US 2004-568765	A1	20041021 (10)
	WO 2004-US34625		20041021
			20070212 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-512923P	20031022 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 1100 13th STREET, N.W., SUITE 1200, WASHINGTON, DC, 20005-4051, US	

NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 16 Drawing Page(s)  
LINE COUNT: 1016

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by spore-laden bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D-24851  
(combination bacteriolytic therapy for the treatment of tumors using spores of anaerobic bacteria and microtubule agents)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 8 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:327584 USPATFULL

TITLE: Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

INVENTOR(S): Roessler, Berthold, Halle/Westfalen, GERMANY, FEDERAL REPUBLIC OF  
Raab, Gerhard, Ronneburg, GERMANY, FEDERAL REPUBLIC OF  
Reissmann, Thomas, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): BAXTER INTERNATIONAL INC., Deerfield, IL, UNITED STATES (U.S. corporation)  
Baxter Healthcare S. A., Wallisellen, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060280787	A1	20061214
APPLICATION INFO.:	US 2005-151459	A1	20050614 (11)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP SHAW PITTMAN, LLP, P.O. BOX 10500, MCLEAN, VA, 22102, US		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	560		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical formulation for oral administration of the poorly soluble and therefore hardly bioavailable microtubule polymerization inhibitor Indibulin and a process for its manufacture. In particular, there is provided a pharmaceutical formulation of Indibulin for oral administration comprising a granulate containing micronized Indibulin having a particle size of less than 20 µm for at least 99% of the volume of particles, at least one hydrophilic surfactant, and at least one capsulation excipient. The present invention also discloses a method of treating hyperproliferative disorders, malignancies and neoplasms with Indibulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, Indibulin  
(oral formulation of micronized tubulin inhibitor indibulin with improved pharmacokinetics for treatment of hyperproliferative disorders and neoplasms)

RN 204205-90-3 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 9 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2006:167882 USPATFULL  
 TITLE: Bis(thio-hydrazide amides) for treatment of hyperplasia  
 INVENTOR(S): Sherman, Matthew L., Newton, MA, UNITED STATES  
 Vaghefi, Farid, Burlington, MA, UNITED STATES  
 Chen, Lan Bo, Lexington, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060142393	A1	20060629
APPLICATION INFO.:	US 2005-226929	A1	20050914 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-610270P	20040916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof.  
 ##STR1## Y is a covalent bond or an optionally substituted straight chained hydrocarbaryl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group.

R.sub.1-R.sub.4 are independently --H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R.sub.1 and R.sub.3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R.sub.2 and R.sub.4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.

R.sub.7-R.sub.8 are independently --H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, Nascapine

(bis(thiohydrazide amides) for treatment of hyperplasia)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 10 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:152317 USPATFULL

TITLE: 4-,6- or 7-hydroxyindoles with N-oxide groups and the use thereof as therapeutic agents

INVENTOR(S): Hofgen, Nobert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF

Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF  
Steinike, Karin, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060128758	A1	20060615
APPLICATION INFO.:	US 2006-342428	A1	20060130 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-825862, filed on 16 Apr 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10318611	20030424
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1-16	
LINE COUNT:	888	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 4-, 6- or 7-hydroxyindoles with N-oxide groups, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 785787-52-2P 785787-53-3P 785787-54-4P  
785787-55-5P 785787-56-6P 785787-57-7P  
785787-58-8P 785787-59-9P 785787-60-2P  
785787-63-5P 785787-65-7P 785787-66-8P

(claimed compound; preparation of hydroxyindolylglyoxylic acid  
oxypyridinylamides as phosphodiesterase IV inhibitors)


RN 785787-52-2 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-  
fluorophenyl)methyl]-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-53-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-1-oxido-  
4-pyridinyl)-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-54-4 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-N-(3,5-dichloro-1-oxido-  
4-pyridinyl)-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)






RN 785787-55-5 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,4-dichlorophenyl)methyl]-7-hydroxy-α-oxo- (CA INDEX NAME)




RN 785787-56-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-7-hydroxy-N-(1-oxido-4-pyridinyl)-α-oxo- (CA INDEX NAME)




RN 785787-57-7 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-4-hydroxy-α-oxo- (CA INDEX NAME)




RN 785787-58-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-[(3-nitrophenyl)methyl]-α-oxo- (CA INDEX NAME)




RN 785787-59-9 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-[(2-nitrophenyl)methyl]-α-oxo- (CA INDEX NAME)




RN 785787-60-2 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,6-difluorophenyl)methyl]-7-hydroxy-α-oxo- (CA INDEX NAME)




RN 785787-63-5 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-[(4-hydroxyphenyl)methyl]-α-oxo- (CA INDEX NAME)



RN 785787-65-7 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-6-hydroxy-α-oxo- (CA INDEX NAME)



RN 785787-66-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-6-hydroxy-N-(1-oxido-4-


pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)



IT 785787-68-0  
(preparation of hydroxyindolylglyoxylic acid oxypyridinylamides as phosphodiesterase IV inhibitors)

RN 785787-68-0 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-7-(phenylmethoxy)- (CA INDEX NAME)



IT 785787-67-9P  
(preparation of hydroxyindolylglyoxylic acid oxypyridinylamides as phosphodiesterase IV inhibitors)

RN 785787-67-9 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-7-(phenylmethoxy)- (CA INDEX NAME)



L9 ANSWER 11 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:130825 USPATFULL

TITLE: Nanoparticulate compositions of tubulin inhibitor compounds

INVENTOR(S): Papadopoulos, Pavlos, Antioch, IL, UNITED STATES  
 Raab, Gerhard, Ronneburg, GERMANY, FEDERAL REPUBLIC OF  
 Doty, Mark J., Grayslake, IL, UNITED STATES  
 Kipp, James E., Wauconda, IL, UNITED STATES  
 Roessler, Berthold, Halle/Westfalen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060110462	A1	20060525
APPLICATION INFO.:	US 2005-266518	A1	20051103 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-626036P	20041108 (60)
	US 2005-642878P	20050111 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Baxter Healthcare Corporation, One Baxter Parkway -  
 DF3-2E, Deerfield, IL, 60015, US

NUMBER OF CLAIMS:

78

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

8 Drawing Page(s)

LINE COUNT:

2388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as "Indibulin," and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D 24851


(Indibulin; particulate compns. of tubulin inhibitors for treatment of resistant cancers and other diseases)

RN 204205-90-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



IT 204205-78-7 204205-80-1 204205-81-2  
204205-82-3 204205-85-6 204205-86-7  
204205-91-4 204205-92-5 204205-95-8  
204205-96-9 204205-97-0 204205-98-1  
204206-01-9 204206-02-0 204206-03-1  
(particulate comps. of tubulin inhibitors for treatment of resistant  
cancers and other diseases)  
RN 204205-78-7 USPATFULL  
CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL  
CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-91-4 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-92-5 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)






RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-98-1 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-02-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204206-03-1 USPATFULL  
 CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 12 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2006:111775 USPATFULL  
 TITLE: Composition comprising a pde4 inhibitor and a pde5 inhibitor  
 INVENTOR(S): Dunkern, Torsten, Stockach, GERMANY, FEDERAL REPUBLIC OF  
 Hatzelmann, Armin, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Schudt, Christian, Konstanz, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060094723	A1	20060504
APPLICATION INFO.:	US 2004-556888	A1	20040519 (10)
	WO 2004-EP50869		20040519
			20051115 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2003-11609	20030522
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES PLLC, 112 South West Street,	

Alexandria, VA, 22314, US  
NUMBER OF CLAIMS: 65  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4, AWD-12-281  
(composition comprising a PDE4 inhibitor and a PDE5 inhibitor)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 13 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:98548 USPATFULL

TITLE: Combination of a pde iv inhibitor and a tn timer-alpha antagonist

INVENTOR(S): Warner, James M, Webster Groves, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060083714	A1	20060420
APPLICATION INFO.:	US 2004-500266	A1	20040123 (10)
	WO 2004-1B616		20040123
			20040618 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442881P	20030127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006, US	

NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1869

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. Particularly

the present invention relates to treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2006:93409 USPATFULL  
 TITLE: Pde4 and pde3/4 inhibitors for use in the treatment of cachexia  
 INVENTOR(S): Schmidt, Mathias, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 PATENT ASSIGNEE(S): Altana Pharma AG, Konstanz, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060079540	A1	20060413
APPLICATION INFO.:	US 2003-535815	A1	20031126 (10)
	WO 2003-EP13313		20031126
			20050520 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-26548	20021127
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES PLLC, 112 South West Street, Alexandria, VA, 22314, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	691	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the use of a PDE4 or PDE3/4 inhibitor for the treatment of cachexia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 257892-33-4 444659-44-3  
 (phosphodiesterase IV and phosphodiesterase III/IV inhibitors for treatment of cachexia)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 444659-44-3 USPATFULL  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 15 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2006:47517 USPATFULL  
 TITLE: Pharmaceutical presentation form for oral administration of a poorly soluble active compound, process for its preparation and kit  
 INVENTOR(S): Roessler, Berthold, Halle, GERMANY, FEDERAL REPUBLIC OF  
 PATENT ASSIGNEE(S): Baxter International Inc., Deerfield, IL, UNITED STATES (U.S. corporation)  
 Baxter Healthcare S.A., Wallisellen, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060040991	A1	20060223
APPLICATION INFO.:	US 2005-169407	A1	20050629 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-102004031	20040629
	US 2004-583815P	20040629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SENNIGER POWERS, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102, US	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	408	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a pharmaceutical presentation form for the oral administration of indibulin in the form of an aqueous drink solution, and a method for its preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 204205-90-3, D24851  
 (aqueous drink solution of indibulin (D-24851) and an organic acid)  
 RN 204205-90-3 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-

pyridinyl- (CA INDEX NAME)



L9 ANSWER 16 OF 38 USPATFULL on STN  
ACCESSION NUMBER: 2006:41241 USPATFULL  
TITLE: Pharmaceutical compositions for treatment of  
respiratory and gastrointestinal disorders  
INVENTOR(S): Jung, Birgit, Biberach, GERMANY, FEDERAL REPUBLIC OF  
Himmelsbach, Frank, Mittelbiberach, GERMANY, FEDERAL  
REPUBLIC OF  
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim,  
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060035893	A1	20060216
APPLICATION INFO.:	US 2005-189643	A1	20050726 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-18808	20040807
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US	

NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 8735  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK.sub.1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 257892-33-4, AWD 12-281

(pharmaceutical compns. for treatment of respiratory and  
gastrointestinal disorders)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[4-

fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 17 OF 38 USPATFULL on STN  
ACCESSION NUMBER: 2006:4585 USPATFULL  
TITLE: 3-glyoxylamideindoles for treating cancer  
INVENTOR(S): Koya, Keizo, Brookline, MA, UNITED STATES  
Sun, Lijun, Harvard, MA, UNITED STATES  
Ono, Mitsunori, Lexington, MA, UNITED STATES  
Liang, Guqing, Concord, MA, UNITED STATES  
James, David, Cambridge, MA, UNITED STATES  
Li, Hao, Brookline, MA, UNITED STATES  
Xia, Zhi-Qiang, Dedham, MA, UNITED STATES  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., Lexington, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060004044	A1	20060105
APPLICATION INFO.:	US 2005-136074	A1	20050524 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-232394, filed on 29 Aug 2002, GRANTED, Pat. No. US 6958348		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-322022P	20010913 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1-20	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1010	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Disclosed is an anti-cancer compound represented by Structural Formula (I): ##STR1## The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).




CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-60-4P 501921-65-9P

(preparation of glyoxylamide indoles as anticancer agents useful against multidrug-resistant cancer cells)


RN 501921-60-4 USPATFULL

CN 1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 18 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2005:331279 USPATFULL

TITLE: Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allergic diseases, asthma and copd

INVENTOR(S): Locher, Mathias, Ronneburg, GERMANY, FEDERAL REPUBLIC OF  
Hermann, Robert, Max-Reger-Str, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050288265	A1	20051229
APPLICATION INFO.:	US 2003-523802	A1	20030804 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-102	20020806
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	VENABLE LLP, P.O. BOX 34385, WASHINGTON, DC, 20045-9998, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	411	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a novel combination of a glucocorticoid, especially lomeprednol, and at least one phospho-diesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or separate administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4

(combination of glucocorticoids and PDE-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and COPD)

RN 257892-33-4 USPTAFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 19 OF 38 USPTAFULL on STN

ACCESSION NUMBER: 2005:268778 USPTAFULL

TITLE: Novel compounds and methods of use thereof

INVENTOR(S): Chen, Chung-Tong, Taipei, TAIWAN, PROVINCE OF CHINA  
Chen, Shu-Jen, Taipei, TAIWAN, PROVINCE OF CHINA  
Hsu, Ming-Chu, Taipei, TAIWAN, PROVINCE OF CHINA  
Hwang, Der-Ren, Taipei, TAIWAN, PROVINCE OF CHINA  
Li, Wen-Tai, Taipei, TAIWAN, PROVINCE OF CHINA  
Lin, Chu-Chung, Taipei, TAIWAN, PROVINCE OF CHINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050234098	A1	20051020


US 7396838 B2 20080708  
 APPLICATION INFO.: US 2005-145628 A1 20050606 (11)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-310711, filed on 5 Dec 2002, GRANTED, Pat. No. US 6903104

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-337962P	20011206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1-37	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2031	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB This invention relates to novel heteroatom containing compounds and compositions thereof, and their use for the prevention and treatment of disease. The invention also provides for methods of making the compounds. The invention is based on the discovery that certain heteroatom containing compounds, 3-oxoacetamideindolyl compounds, have potent anticancer, cytotoxic, and anti-angiogenic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-65-9P, N-(4-Pyridyl)-2-[1-(4-cyanobenzyl)-1H-indol-3-yl]-2-oxoacetamide  
 (preparation of (3-indolyl)oxoacetamide derivs. as angiogenesis inhibitors and anticancer agents)  
 RN 501921-65-9 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 20 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:203253 USPATFULL  
 TITLE: Compounds and method for coating surfaces in a haemocompatible manner  
 INVENTOR(S): Horres, Roland, Stolberg, GERMANY, FEDERAL REPUBLIC OF  
 Linssen, Marita Katarina, Aachen, GERMANY, FEDERAL REPUBLIC OF  
 Hoffmann, Michael, Eschweiler, GERMANY, FEDERAL REPUBLIC OF  
 Hoffmann, Erika, Eschweiler, GERMANY, FEDERAL REPUBLIC OF  
 Di Baise, Donato, Aachen, GERMANY, FEDERAL REPUBLIC OF

Faust, Volker, Aachen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050176678	A1	20050811
APPLICATION INFO.:	US 2003-513982	A1	20030415 (10)
	WO 2003-DE1253		20030415

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10221055	20020510
	US 2003-378676P	20020509 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Gregory Turocy, Amin & Turocy, National City Center,  
1900 East 9th Street 24th Floor, Cleveland, OH, 44114,  
US  
NUMBER OF CLAIMS: 51  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 13 Drawing Page(s)  
LINE COUNT: 2492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D-24851

(medical goods comprising a heparin-based hemocompatible coating)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 21 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:171786 USPATFULL  
 TITLE: IAP nucleobase oligomers and oligomeric complexes and uses thereof  
 INVENTOR(S): LaCasse, Eric, Ottawa, CANADA  
 McManus, Daniel, Ottawa, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050148535	A1	20050707
APPLICATION INFO.:	US 2004-975974	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516192P	20031030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US	

NUMBER OF CLAIMS: 48  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 15 Drawing Page(s)  
 LINE COUNT: 3022

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D 24851  
 (human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)

RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 22 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:150820 USPATFULL  
 TITLE: Biocompatible, biostable coating of medical surfaces

INVENTOR(S): Horres, Roland, Stolberg, GERMANY, FEDERAL REPUBLIC OF  
 Hoffmann, Michael, Eschweiler, GERMANY, FEDERAL  
 REPUBLIC OF  
 Faust, Volker, Aachen, GERMANY, FEDERAL REPUBLIC OF  
 Hoffmann, Erika, Eschweiler, GERMANY, FEDERAL REPUBLIC  
 OF  
 Di Biase, Donato, Aachen, GERMANY, FEDERAL REPUBLIC OF


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050129731	A1	20050616
APPLICATION INFO.:	US 2004-979977	A1	20041103 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516295P	20031103 (60)
	US 2004-571582P	20040517 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMIN & TUROCY, LLP, 1900 EAST 9TH STREET, NATIONAL CITY CENTER, 24TH FLOOR,, CLEVELAND, OH, 44114, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1791	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention relates to medical products with at least one biocompatible biostable polysulfone coating with which the elution kinetics of the incorporated and/or deposited at least one antiproliferative, antiinflammatory, antiphlogistic and/or antithrombotic active agent can be controlled via the admixing of at least one hydrophilic polymer in a suitable amount and as well as an local separation of different active agents and active agent combinations respectively can be achieved by means of the layer system of biostable polymers, methods of manufacturing these medical products as well as their use especially in the form of stents for prevention of restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D-24851  
 (biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)  
 RN 204205-90-3 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




L9 ANSWER 23 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:138567 USPATFULL  
 TITLE: Methods and reagents for the treatment of proliferative diseases  
 INVENTOR(S): LaCasse, Eric, Ottawa, CANADA  
 McManus, Daniel, Ottawa, CANADA  
 Durkin, Jon P., Montreal, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050119217	A1	20050602
APPLICATION INFO.:	US 2004-975790	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516263P	20031030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	5896	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention features methods, compositions, and kits for treating a patient having a proliferative disease.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-90-3, D 24851  
 (sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent)  
 RN 204205-90-3 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 24 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:130611 USPATFULL  
 TITLE: Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist  
 INVENTOR(S): Beume, Rolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Bundschuh, Daniela, Konstanz, GERMANY, FEDERAL REPUBLIC OF

Weimar, Christian, Konstanz, GERMANY, FEDERAL REPUBLIC  
OF  
Wollin, Stefan-Lutz, Meersburg, GERMANY, FEDERAL  
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050112069	A1	20050526
APPLICATION INFO.:	US 2003-506875	A1	20030225 (10)
	WO 2003-EP1876		20030225

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-4987	20020306
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES PLLC, 1030 FIFTEENTH STREET, N.W., SIXTH FLOOR, WASHINGTON, DC, 20005, US	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3309	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4, AWD 12-281 444659-44-3, AWD 12-343  
(phosphodiesterase 4 (PDE4) inhibitor or PDE3/4 inhibitor combination with histamine receptor antagonist for treatment of respiratory disease)

RN 257892-33-4 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 444659-44-3 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)





L9 ANSWER 25 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2005:17360 USPATFULL  
 TITLE: Combination  
 INVENTOR(S): Beume, Rolf, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Bundschuh, Daniela, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Weimar, Christian, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Wollin, Stefan-Lutz, Meersburg, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050014762	A1	20050120
APPLICATION INFO.:	US 2004-489903	A1	20040818 (10)
	WO 2002-EP10423		20020917

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2001-474	20010919
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES, 1030 15th STREET, NW, 6TH FLOOR, WASHINGTON, DC, 20005	

NUMBER OF CLAIMS: 34  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 3 Drawing Page(s)  
 LINE COUNT: 1162

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and leukotriene receptor antagonists for the treatment of respiratory tract disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4 444659-44-3, AWD 12-343  
 (phosphodiesterase inhibitor; combined administration of  
 phosphodiesterase PDE4 or PDE3/4 inhibitors and leukotriene receptor  
 antagonists for treatment of respiratory tract disorders)


RN 257892-33-4 USPATFULL

CN 1H-indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 444659-44-3 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo- (CA INDEX NAME)



L9 ANSWER 26 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2004:335668 USPATFULL

TITLE: Indole derivatives having an apoptosis-inducing effect

INVENTOR(S): Gerlach, Matthias, Brachtal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040266762	A1	20041230
	US 7205299	B2	20070417
APPLICATION INFO.:	US 2004-858751	A1	20040602 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2003-12868	20030606
	EP 2004-11598	20040515
	US 2003-476277P	20030605 (60)
	US 2003-476794P	20030606 (60)
	US 2004-572025P	20040517 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GOODWIN PROCTER L.L.P., 103 EISENHOWER PARKWAY,

ROSELAND, NJ, 07068

NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 1080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to indole derivatives which are used as drugs for treating tumor diseases, in particular when there is drug resistance against other active compounds and where there is a metastasizing carcinoma.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 804551-60-8P, 2-[1-(4-Chlorobenzyl)-1H-indol-3-yl]-2-oxo-N-pyrido[2,3-b]pyrazin-7-ylacetamide  
(preparation of chlorobenzylindoles as tubulin polymerization inhibitors

with  
apoptosis inducing activity)

RN 804551-60-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-pyrido[2,3-b]pyrazin-7-yl- (CA INDEX NAME)



L9 ANSWER 27 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2004:335666 USPATFULL

TITLE: 5-hydroxyindoles with N-oxide groups and the use thereof as therapeutic agents

INVENTOR(S): Hofgen, Nobert, Ottendorf-Okilla, GERMANY, FEDERAL REPUBLIC OF  
Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF  
Steinike, Karin, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF  
Pfeifer, Thomas, Radebeul, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040266760	A1	20041230
APPLICATION INFO.:	US 2004-824342	A1	20040414 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10318609	20030424
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY,  
 10103-3198  
 NUMBER OF CLAIMS: 19  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 850

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 5-hydroxyindoles with N-oxide groups, processes for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 786688-50-4P 786688-51-5P 786688-52-6P  
 786688-53-7P 786688-54-8P 786688-55-9P  
 786688-58-2P

(claimed compound; preparation of oxypyridinyl hydroxyindolylglyoxylamides

as phosphodiesterase IV inhibitors)


RN 786688-50-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)




RN 786688-51-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-1-oxido-4-pyridinyl)-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)




RN 786688-52-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-hydroxy-N-(1-oxido-4-pyridinyl)-α-oxo- (CA INDEX NAME)



RN 786688-53-7 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,4-dichlorophenyl)methyl]-5-hydroxy-α-oxo- (CA INDEX NAME)



RN 786688-54-8 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-5-hydroxy-1-

[(3-nitrophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 786688-55-9 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,6-difluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 786688-58-2 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-5-hydroxy-1-[(4-hydroxyphenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




IT 656237-85-3

(preparation of oxypyridinyl hydroxyindolylglyoxylamides as

phosphodiesterase IV inhibitors)  
 RN 656237-85-3 USPATFULL  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-5-(phenylmethoxy)- (CA INDEX NAME)



IT 786688-60-6P  
 (preparation of oxypyridinyl hydroxyindolylglyoxylamides as  
 phosphodiesterase IV inhibitors)  
 RN 786688-60-6 USPATFULL  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-5-(phenylmethoxy)- (CA INDEX NAME)



L9 ANSWER 28 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2004:307967 USPATFULL  
 TITLE: 4-,6- or 7-hydroxyindoles with N-oxide groups and the  
 use thereof as therapeutic agents  
 INVENTOR(S): Hofgen, Nobert, Ottendorf-Okrilla, GERMANY, FEDERAL  
 REPUBLIC OF  
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF  
 Steinike, Karin, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
 Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
 Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 20040242643 A1 20041202  
 US 7067536 B2 20060627  
 APPLICATION INFO.: US 2004-825862 A1 20040416 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10318611	20030424
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	870	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		


AB The invention relates to substituted 4-,6- or 7-hydroxyindoles with N-oxide groups, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 785787-52-2P 785787-53-3P 785787-54-4P  
 785787-55-5P 785787-56-6P 785787-57-7P  
 785787-58-8P 785787-59-9P 785787-60-2P  
 785787-63-5P 785787-65-7P 785787-66-8P  
 (claimed compound; preparation of hydroxyindolylglyoxylic acid oxypyridinylamides as phosphodiesterase IV inhibitors)

RN 785787-52-2 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-53-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)






RN 785787-54-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-α-oxo- (CA INDEX NAME)



RN 785787-55-5 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,4-dichlorophenyl)methyl]-7-hydroxy-α-oxo- (CA INDEX NAME)



RN 785787-56-6 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-7-hydroxy-N-(1-oxido-4-

pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 785787-57-7 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-4-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-58-8 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-[(3-nitrophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-59-9 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-

[(2-nitrophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 785787-60-2 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(2,6-difluorophenyl)methyl]-7-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-63-5 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-7-hydroxy-1-[(4-hydroxyphenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-65-7 USPATFULL


CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-

fluorophenyl)methyl]-6-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 785787-66-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-6-hydroxy-N-(1-oxido-4-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




IT 785787-68-0

(preparation of hydroxyindolylglyoxylic acid oxypyridinylamides as phosphodiesterase IV inhibitors)

RN 785787-68-0 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-7-(phenylmethoxy)- (CA INDEX NAME)




IT 785787-67-9P

(preparation of hydroxyindolylglyoxylic acid oxopyridinylamides as phosphodiesterase IV inhibitors)

RN 785787-67-9 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-7-(phenylmethoxy)- (CA INDEX NAME)



L9 ANSWER 29 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2004:221896 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

INVENTOR(S): Nickel, Bernd, Muhlthal, GERMANY, FEDERAL REPUBLIC OF  
Bacher, Gerald, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
Klenner, Thomas, Ingelheim, GERMANY, FEDERAL REPUBLIC OF  
Beckers, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
Engel, Jurgen, Alzenau, GERMANY, FEDERAL REPUBLIC OF  
Bruyneel, Erik, Harelbeke, BELGIUM  
Kamp, Gunter, Munster, GERMANY, FEDERAL REPUBLIC OF  
Peters, Kirsten, Munster, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): Baxter Healthcare SA, Wallisellen, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040171668	A1	20040902
APPLICATION INFO:	US 2003-686809	A1	20031017 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-492531, filed on 27 Jan 2000, GRANTED, Pat. No. US 6693119		
	Continuation-in-part of Ser. No. US 1999-285058, filed on 2 Apr 1999, GRANTED, Pat. No. US 6232327		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19946301	19990828
	DE 1998-19814838	19980402

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:


PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA,

22102  
 NUMBER OF CLAIMS: 13  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 9 Drawing Page(s)  
 LINE COUNT: 570  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention relates to the use of N-substituted indole-3-glyoxylamides  
 of the general Formula I: ##STR1##


and to pharmaceutical compositions having antitumor action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
 204205-82-3P 204205-85-6P 204205-86-7P  
 204205-90-3P 204205-91-4P 204205-92-5P  
 204205-95-8P 204205-96-9P 204205-97-0P  
 204206-01-9P 204206-03-1P 245661-24-9P  
 245661-25-0P 245661-26-1P 245661-28-3P  
 245661-29-4P 245661-30-7P 245661-31-8P  
 245661-38-5P 245661-39-6P 245661-41-0P  
 245661-42-1P 245661-43-2P 245661-47-6P  
 245661-48-7P 245661-49-8P 245661-50-1P  
 245661-51-2P 245661-52-3P 245661-53-4P  
 245661-54-5P 245661-55-6P  
 (preparation of indolyglyoxylamides as antitumor agents)  
 RN 204205-78-7 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-  
 pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-  
 pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-90-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-91-4 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-  
pyridinyl- (CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (CA INDEX NAME)



RN 245661-38-5 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 245661-39-6 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester

(9C1) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-50-1 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-51-2 USPATFULL


CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)






RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 30 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2004:51527 USPATFULL  
 TITLE: Topical treatment of skin diseases  
 INVENTOR(S): Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF  
 Kietzmann, Manfred, Grossburgwedel, GERMANY, FEDERAL REPUBLIC OF  
 Hoppmann, Joachim, Radebeul, GERMANY, FEDERAL REPUBLIC OF  
 Baumer, Wolfgang, Hannover, GERMANY, FEDERAL REPUBLIC OF  
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF  
 Hofgen, Norbert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040038958	A1	20040226
APPLICATION INFO.:	US 2003-611649	A1	20030701 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-395221P	20020711 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY,	

10103-3198  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Page(s)  
LINE COUNT: 951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 257892-33-4, AWD 12-281  
(phosphodiesterase inhibitors for treatment of skin inflammatory and/or allergic reactions)

RN 257892-33-4 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 31 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2003:277333 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having antitumor action

INVENTOR(S): Nickel, Bernd, Muhlital, GERMANY, FEDERAL REPUBLIC OF  
Szelenyi, Istvan, Schwaig, GERMANY, FEDERAL REPUBLIC OF  
Schmidt, Jurgen, Uhldingen Muhlhofen, GERMANY, FEDERAL REPUBLIC OF  
Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
Reichert, Dietmar, Eschau, GERMANY, FEDERAL REPUBLIC OF  
Gunther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF  
Brune, Kay, Marloffstein, GERMANY, FEDERAL REPUBLIC OF  
Le Baut, Guillaume, Saint Sebastian/Loire, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft (non-U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030195360	A1	20031016
APPLICATION INFO.:	US 2002-309204	A1	20021204 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-810604, filed on 19 Mar 2001, PENDING Continuation of Ser. No. US 1999-285058, filed on 2 Apr 1999, GRANTED, Pat. No. US 6232327		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1007	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents ##STR1##	

and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
 204205-82-3P 204205-85-6P 204205-86-7P  
 204205-90-3P 204205-91-4P 204205-92-5P  
 204205-95-8P 204205-96-9P 204205-97-0P  
 204206-01-9P 204206-03-1P 245661-24-9P  
 245661-25-0P 245661-26-1P 245661-28-3P  
 245661-29-4P 245661-30-7P 245661-31-8P  
 245661-38-5P 245661-39-6P 245661-41-0P  
 245661-42-1P 245661-43-2P 245661-47-6P  
 245661-48-7P 245661-49-8P 245661-50-1P  
 245661-51-2P 245661-52-3P 245661-53-4P  
 245661-54-5P 245661-55-6P  
 (preparation of indolylglyoxylamides as antitumor agents)  
 RN 204205-78-7 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 204206-01-9 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204206-03-1 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
α-oxo- (CA INDEX NAME)



RN 245661-38-5 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA  
INDEX NAME)



RN 245661-39-6 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester

(9C1) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 32 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2003:258429 USPATFULL  
 TITLE: Novel compounds and methods of use thereof  
 INVENTOR(S): Chen, Chiung-Tong, Taipei, TAIWAN, PROVINCE OF CHINA  
 Chen, Shu-Jen, Taipei, TAIWAN, PROVINCE OF CHINA  
 Hsu, Ming-Chu, Taipei, TAIWAN, PROVINCE OF CHINA  
 Hwang, Der-Ren, Taipei, TAIWAN, PROVINCE OF CHINA  
 Li, Wen-Tai, Taipei, TAIWAN, PROVINCE OF CHINA  
 Lin, Chu-Chung, Taipei, TAIWAN, PROVINCE OF CHINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030181482	A1	20030925
	US 6903104	B2	20050607
	US 2002-310711	A1	20021205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337962P	20011206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY D. HSI, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	



NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 2068

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB This invention relates to novel heteroatom containing compounds and compositions thereof, and their use for the prevention and treatment of disease. The invention also provides for methods of making the compounds. The invention is based on the discovery that certain heteroatom containing compounds, 3-oxoacetamideindolyl compounds, have potent anticancer, cytotoxic, and anti-angiogenic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-65-9P, N-(4-Pyridyl)-2-[1-(4-cyanobenzyl)-1H-indol-3-yl]-2-oxoacetamide  
(preparation of (3-indolyl)oxoacetamide derivs. as angiogenesis inhibitors and anticancer agents)

RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)



L9 ANSWER 33 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2003:166653 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

INVENTOR(S): Nickel, Bernd, Muhlthal, GERMANY, FEDERAL REPUBLIC OF  
Bacher, Gerald, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
Klenner, Thomas, Ingelheim, GERMANY, FEDERAL REPUBLIC OF  
Beckers, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
Engel, Jurgen, Alzenau, GERMANY, FEDERAL REPUBLIC OF  
Bruyneel, Erik, Harelbeke, BELGIUM  
Kamp, Gunter, Munster, GERMANY, FEDERAL REPUBLIC OF  
Peters, Kirsten, Munster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030114511	A1	20030619
	US 6693119	B2	20040217
APPLICATION INFO.:	US 2000-492531	A1	20000127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402

DE 1999-19946301 19990928  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102  
NUMBER OF CLAIMS: 13  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 9 Drawing Page(s)  
LINE COUNT: 576  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The object of the invention is then to widen the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available pharmaceutical wealth. The possibility of a lower, longer-lasting and better-tolerable medication for the class of substances having antitumor action described in German Patent Application 19814 838.0 should thus be opened up. In particular, the disadvantageous development of resistance, as is known of many antitumor agents, should be circumvented.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
204205-82-3P 204205-85-6P 204205-86-7P  
204205-90-3P 204205-91-4P 204205-92-5P  
204205-95-8P 204205-96-9P 204205-97-0P  
204206-01-9P 204206-03-1P 245661-24-9P  
245661-25-0P 245661-26-1P 245661-28-3P  
245661-29-4P 245661-30-7P 245661-31-8P  
245661-38-5P 245661-39-6P 245661-41-0P  
245661-42-1P 245661-43-2P 245661-47-6P  
245661-48-7P 245661-49-8P 245661-50-1P  
245661-51-2P 245661-52-3P 245661-53-4P  
245661-54-5P 245661-55-6P  
(preparation of indolylglyoxylamides as antitumor agents)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)



RN 245661-29-4 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-  
pyridinyl- (CA INDEX NAME)



RN 245661-30-7 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)






RN 245661-31-8 USPATFULL

CN 1H-indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
α-oxo- (CA INDEX NAME)



RN 245661-38-5 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA  
INDEX NAME)



RN 245661-39-6 USPATFULL


CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester

(9C1) (CA INDEX NAME)




RN 245661-41-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-42-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[[4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 34 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2003:134662 USPATFULL  
 TITLE: 3-glyoxylamideindoles for treating cancer  
 Koya, Keizo, Brookline, MA, UNITED STATES  
 INVENTOR(S): Sun, Lijun, Harvard, MA, UNITED STATES  
 Ono, Mitsunori, Lexington, MA, UNITED STATES  
 Liang, Guiqing, Concord, MA, UNITED STATES  
 James, David, Cambridge, MA, UNITED STATES  
 Li, Hao, Brookline, MA, UNITED STATES  
 Xia, Zhi-Qiang, Dedham, MA, UNITED STATES  
 PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., Lexington, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030092751	A1	20030515
	US 6958348	B2	20051025
APPLICATION INFO.:	US 2002-232394	A1	20020829 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-322022P	20010913 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA	

ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

NUMBER OF CLAIMS: 42  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 1151

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is an anti-cancer compound represented by Structural  
Formula (I): ##STR1##


The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 501921-60-4P 501921-65-9P  
(preparation of glyoxylamide indoles as anticancer agents useful against multidrug-resistant cancer cells)


RN 501921-60-4 USPATFULL

CN 1H-Indole-3-acetamide, N-[5-(aminocarbonyl)-2-pyridinyl]-1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



RN 501921-65-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-cyanophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 35 OF 38 USPATFULL on STN  
 ACCESSION NUMBER: 2003:31141 USPATFULL  
 TITLE: United states patent office  
 INVENTOR(S): Nickel, Bernd, Muhltal, GERMANY, FEDERAL REPUBLIC OF  
 Szelenyi, Istvan, Schwaig, GERMANY, FEDERAL REPUBLIC OF  
 Schmidt, Jurgen, Uhlhingen Muhlhofen, GERMANY, FEDERAL  
 REPUBLIC OF  
 Emig, Peter, Bruchkobel, GERMANY, FEDERAL REPUBLIC OF  
 Reichert, Dietmar, Eschau, GERMANY, FEDERAL REPUBLIC OF  
 Gunther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF  
 Brune, Kay, Marloffstein, GERMANY, FEDERAL REPUBLIC OF  
 Le Baut, Guillaume, Saint Sebastian/Loire, FRANCE  
 PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030023093	A1	20030130
APPLICATION INFO.:	US 2001-810604	A1	20010319 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1036	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents ##STR1##

and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations



which can be employed by inhalation, suspensions, creams and ointments.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 204205-78-7P 204205-80-1P 204205-81-2P  
204205-82-3P 204205-85-6P 204205-86-7P  
204205-90-3P 204205-91-4P 204205-92-5P  
204205-95-8P 204205-96-9P 204205-97-0P  
204206-01-9P 204206-03-1P 245661-24-9P  
245661-25-0P 245661-26-1P 245661-28-3P  
245661-29-4P 245661-30-7P 245661-31-8P  
245661-38-5P 245661-39-6P 245661-41-0P  
245661-42-1P 245661-43-2P 245661-47-6P  
245661-48-7P 245661-49-8P 245661-50-1P  
245661-51-2P 245661-52-3P 245661-53-4P  
245661-54-5P 245661-55-6P

(preparation of indolylglyoxylamides as antitumor agents)


RN 204205-78-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-90-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 204205-92-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy-α-oxo-N-(4-pyridinyl)- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245661-39-6 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 245661-41-0 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-42-1 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



L9 ANSWER 36 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2002:192036 USPATFULL

TITLE: Methods of inducing ovulation


INVENTOR(S): Palmer, Stephen, Plympton, MA, UNITED STATES  
 McKenna, Sean, Duxbury, MA, UNITED STATES  
 Tepper, Mark, Canton, MA, UNITED STATES  
 Eshkol, Aliza, La Rippe, SWITZERLAND  
 Macnamee, Michael C., Cambridgeshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020103106	A1	20020801
	US 6953774	B2	20051011
APPLICATION INFO.:	US 2001-14812	A1	20011214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-928268, filed on 10 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-224962P	20000811 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1402	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		


AB The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 257892-33-4, AWD-12-281 444659-44-3  
 (methods of inducing ovulation by administering a non-polypeptide cAMP level modulator)  
 RN 257892-33-4 USPATFULL  
 CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy- $\alpha$ -oxo- (CA INDEX NAME)



RN 444659-44-3 USPATFULL

CN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (CA INDEX NAME)



L9 ANSWER 37 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2001:134241 USPATFULL

TITLE: Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action

INVENTOR(S): Gunter, Eckhard, Maintal, Germany, Federal Republic of  
Emig, Peter, Bruchkobel, Germany, Federal Republic of  
Reichert, Dietmar, Eschau, Germany, Federal Republic of  
Le Baut, Guillaume, Saint Sebastian/Loire, France  
Nickel, Bernd, Muhltal, Germany, Federal Republic of  
Bacher, Gerald, Heidelberg, Germany, Federal Republic of

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20010014690	A1	20010816
	US 6432987	B2	20020813
APPLICATION INFO.:	US 2000-736431	A1	20001215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19962300	19991223
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PILLSBURY WINTHROP LLP, 1600 TYSONS BOULEVARD, MCLEAN, VA, 22102	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	586	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel, substituted N-benzyl-indol-3-ylglyoxylic acid derivatives of the following formula and their use for the treatment of oncoses ##STR1##

The invention further relates to their physiologically tolerable acid addition salts and if possible their N-oxides. In addition, the invention relates to pharmaceutical preparations containing at least one of the compounds of the abovementioned formula or their salts or N-oxides with physiologically tolerable inorganic or organic acids and, if appropriate, pharmaceutically utilizable vehicles and/or diluents or excipients and also administration forms of the compounds of the

abovementioned formula containing at least one of the compounds of this formula or their salts in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 344799-93-5P

(preparation of pyridinyl aminobenzylindolylglyoxylamides as antitumor agents)

RN 344799-93-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-nitrophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)




IT 344799-91-3P

(preparation of pyridinyl aminobenzylindolylglyoxylamides as antitumor agents)

RN 344799-91-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-aminophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-  
(CA INDEX NAME)



L9 ANSWER 38 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2001:71562 USPATFULL

TITLE: Indolyl-3-glyoxylic acid derivatives having antitumor action

INVENTOR(S): Nickel, Bernd, Muhlital, Germany, Federal Republic of  
Szelenyi, Istvan, Schwaig, Germany, Federal Republic of  
Schmidt, Jurgen, Uhldingen Muhlhofen, Germany, Federal Republic of

## PATENT ASSIGNEE(S):

Emig, Peter, Bruchkobel, Germany, Federal Republic of  
Reichert, Dietmar, Eschau, Germany, Federal Republic of  
Gunther, Eckhard, Maintal, Germany, Federal Republic of  
Brune, Kay, Marloffstein, Germany, Federal Republic of  
Asta Medica Aktiengesellschaft, Dresden, Germany,  
Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232327	B1	20010515
APPLICATION INFO.:	US 1999-285058		19990402 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19814838	19980402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Desai, Rita	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	957	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents ##STR1##

and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 204205-78-7P 204205-80-1P 204205-81-2P  
204205-82-3P 204205-85-6P 204205-86-7P  
204205-90-3P 204205-91-4P 204205-92-5P  
204205-95-8P 204205-96-9P 204205-97-0P  
204206-01-9P 204206-03-1P 245661-24-9P  
245661-25-0P 245661-26-1P 245661-28-3P  
245661-29-4P 245661-30-7P 245661-31-8P  
245661-38-5P 245661-39-6P 245661-41-0P  
245661-42-1P 245661-43-2P 245661-47-6P  
245661-48-7P 245661-49-8P 245661-50-1P  
245661-51-2P 245661-52-3P 245661-53-4P  
245661-54-5P 245661-55-6P  
(preparation of indolylglyoxylamides as antitumor agents)  
RN 204205-78-7 USPATFULL  
CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 204205-80-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-81-2 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-1-(phenylmethyl)-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-82-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]- $\alpha$ -oxo-N-3-pyridinyl- (CA INDEX NAME)




RN 204205-85-6 USPATFULL

CN 1H-Indole-3-acetamide, N-(2-chloro-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
α-oxo- (CA INDEX NAME)




RN 204205-86-7 USPATFULL

CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-4-pyridinyl- (CA  
INDEX NAME)




RN 204205-90-3 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-  
pyridinyl- (CA INDEX NAME)




RN 204205-91-4 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(2-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 204205-92-5 USPATFULL  
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-95-8 USPATFULL  
 CN 1H-Indole-3-acetamide, α-oxo-1-(phenylmethyl)-N-2-pyridinyl- (CA INDEX NAME)




RN 204205-96-9 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204205-97-0 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 204206-01-9 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-methoxy-α-oxo-N-(4-pyridinyl)- (CA INDEX NAME)




RN 204206-03-1 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 245661-24-9 USPATFULL

CN 1H-Indole-3-acetamide, 5-fluoro-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-25-0 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-26-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-28-3 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-bromophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-29-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(3-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-30-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(1-oxido-4-pyridinyl)-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-31-8 USPATFULL

CN 1H-Indole-3-acetamide, N-(4-amino-3-pyridinyl)-1-[(4-fluorophenyl)methyl]-  
 $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-38-5 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245661-39-6 USPATFULL

CN Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 245661-41-0 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-6-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-42-1 USPATFULL


CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-5-nitro-α-oxo-N-4-pyridinyl- (CA INDEX NAME)






RN 245661-43-2 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-47-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 245661-48-7 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 204205-90-3

CMF C22 H16 Cl N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 245661-49-8 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-50-1 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,6-dichlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl- (CA INDEX NAME)




RN 245661-51-2 USPATFULL

CN Carbamic acid, [1-[(4-fluorophenyl)methyl]-3-[oxo(4-pyridinylamino)acetyl]-1H-indol-5-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 245661-52-3 USPATFULL

CN 1H-Indole-3-acetamide,  $\alpha$ -oxo-N-4-pyridinyl-1-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 245661-53-4 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-2-pyridinyl)- $\alpha$ -oxo- (CA INDEX NAME)




RN 245661-54-5 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(4-methylphenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



RN 245661-55-6 USPATFULL

CN 1H-Indole-3-acetamide, 1-[(2,4-dichlorophenyl)methyl]-α-oxo-N-4-pyridinyl- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 12:59:53 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 13:01:27 ON 14 JUL 2008

L1 STRUCTURE UPLOADED  
L2 138 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:02:30 ON 14 JUL 2008

L3 112 S L2  
L4 16 S L3 NOT PY>2003  
L5 4 S L4 AND (CANCER? OR ?TUMOR?)  
L6 45 S L3 AND (CANCER? OR ?TUMOR?)  
L7 7 S L6 NOT PY>2004

FILE 'WPIDS, USPATFULL' ENTERED AT 13:05:21 ON 14 JUL 2008

L8 83 S L2  
L9 38 S L8 AND (CANCER? OR ?TUMOR?)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	257.99	512.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.80

STN INTERNATIONAL LOGOFF AT 13:12:35 ON 14 JUL 2008